Second Quarter Results to June 30, 2009

Shire plc
August 5, 2009

Angus Russell
Chief Executive Officer

Michael Cola
President, Specialty Pharmaceuticals

Graham Hetherington
Chief Financial Officer

Sylvie Grégoire
President, Shire HGT

Shire

Our purpose
We enable people with life-altering conditions to lead better lives

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Agenda

• Opening remarks	Angus Russell
• Financial review	Graham Hetherington
• Specialty Pharma update	Michael Cola
• HGT update	Sylvie Grégoire
• Concluding remarks	Angus Russell
• Q & A	All

Opening remarks

Angus Russell
CEO

Our purpose
We enable people with life-altering conditions to lead better lives

Core product portfolio delivering strong growth

- Product sales excluding AXR up 20% to $491 million
  - Up 27% on CER basis
- Non GAAP earnings per ADS* : $0.60
- Cash generation of $192 million
- 2009 guidance framework reaffirmed

* Non GAAP diluted earnings per ADS (using full year expected tax rate: 24%) : **$0.47**

New phase of Shire's development

- Delivering solid earnings through excellent execution
  - Proactive cost management
- Continuing globalization efforts to reduce reliance on US market
  - Presence in 26 countries
- Launching new products
  - INTUNIV – Q4 2009
  - velaglucerase alfa - 2010

H2 2009 Key events

H2-09

- INTUNIV launch
- velaglucerase alfa submission US/EU
- DAYTRANA adolescent sNDA filing
- Carrierwave programs progressed
- FIRAZYR self admin trial initiation
- MLD Phase 2/3 initiation
- PLICERA Phase 2 data
- SPD550 Phase 2 data

Financial Review

Graham Hetherington
CFO

Our purpose
We enable people with life-altering conditions to lead better lives

2009 Q2 Performance summary

	Q2 2009 $m	Q2 2008 $m	Reported Growth	Like for Like Growth [2]
Product sales (excl ADDERALL XR)	491	410	+20%	+27%
Product Sales	558	706	-21%	-17%
Total Revenues	630	776	-19%	-15%
EBITDA [1]	140	264	-47%	
EPS - ADS (diluted) [1]	$0.60	$0.95	-36%	
EPS - ADS (diluted - at 24% tax rate)[1]	$0.47			
Cash generation [1]	192	352	-45%	

(1) These are non GAAP financial measures. See appendix for a list of items excluded from the GAAP equivalent to calculate these measures.
(2) 'Like for Like Growth' excludes movements in average exchange rates, and is calculated after restating Q2 2009 results using Q2 2008 average foreign exchange rates.

2009 Q2 Total revenues

	Q2 2009 $m	Q2 2008 $m	Reported Growth	Like for Like Growth (1)
Products sales (excl ADDERALL XR)	491	410	+20%	+27%
ADDERALL XR	67	296	-77%	-77%
Total Product Sales	558	706	-21%	-17%
Royalties	67	65	+3%	+6%
Other Revenues	5	5	-14%	-6%
Total Revenues	630	776	-19%	-15%

(1) 'Like for Like Growth' excludes movements in average exchange rates, and is calculated after restating Q2 2009 results using Q2 2008 average foreign exchange rates.

ADDERALL XR Net sales

	2008 Q4	2009 Q1	2009 Q2	Second half 2009 trend
TRx ('000s)	2,281	2,288	1,181	
Value per TRx	$174.46	$209.53	$210.20	
Demand sales	**$398m**	**$479m**	**$248m**	Continued impact of erosion
Supply chain destocking	($29)	($16)	($67)	Reduced $ destocking per quarter
Gross sales	**$369m**	**$463m**	**$181m**	
Sales deductions	($99)	($173)	($131)	In line with lower demand versus Q2 Lower sales deduction percentage (see below)
Net sales - US	**$270m**	**$290m**	**$50m**	
Net sales - Canada	$5m	$6m	$6m	
Net sales - Teva	-	-	$11m	Q2 included initial Teva stocking
Total revenue	**$275m**	**$296m**	**$67m**	
Sales deductions - US				
as % of Gross sales	27%	37%	72%	Estimate: 55-65% range subject to mix

New Phase for Shire

Q2 2007



Q2 2009



Product sales $504m $558m

2009 Q2 Portfolio strength and diversity

	Q2 2009 $m	Reported Growth	Like for Like Growth (1)
VYVANSE	114	+75%	+75%
ELAPRASE	85	+6%	+15%
LIALDA / MEZAVANT	55	+71%	+73%
PENTASA	54	+21%	+21%
FOSRENOL	50	+17%	+26%
REPLAGAL	44	-1%	+14%
OTHER	89	-11%	-
PRODUCTS EXCLUDING ADDERALL XR	**491**	**+20%**	**+27%**

Q2 2009 Product sales



(1) 'Like for Like Growth' excludes movements in average exchange rates, and is calculated after restating Q2 2009 results using Q2 2008 average foreign exchange rates.

2009 Q2 Cash flow

Millions of USD



Cash and cash equivalents at December 31, 2008	**247**
Cash inflow to June 30, 2009	52
Cash and cash equivalents as at June 30, 2009 (1)	**299**
Convertible Debt	(1,100)
Net debt at June 30, 2009 (2)	**(801)**

(1) Shire's balance of cash and cash equivalents at June 30, 2009 includes $36m of restricted cash.

(2) Shire has a revolving credit facility of $1.2bn which was undrawn at June 30, 2009.

Emerging shape of 2009 income statement

	2009 Q1	2009 Q2	Second half Direction	Second half Dynamics
Gross margin	89%	84%	↑	Growth of higher margin products Moderation of XR erosion/mix effect
R&D	$117m	$118m	↑	Continued investment in new products Velaglucerase program acceleration In-licensing activities
versus 2008	+$8m	-$9m		
SG&A	$272m	$285m	↑	Velaglucerase program acceleration Less favourable foreign exchange in H2 Continued proactive cost management
versus 2008	-$26m	-$14m		
Tax Rate	24%	2%	↑	Q2 benefited from one-time Massachusetts State tax credit H2 Transfer pricing & 2008 tax filing adjustments Full year guidance (24%) unchanged

2009 Guidance maintained

$3.00 ← **EPS-ADS PLANNING RANGE AT OCT YTD 2008 FOREX** → **$3.40**

€1 : $1.52 £1 : $1.95

Aggressive XR erosion curve ⟷ Scheduled drug XR erosion curve

Multiple generics from 1 Oct ⟷ Only two authorised generics as of 1 Oct

Continued growth in new products

Aggressive cost base management

Continued investment in future growth drivers

$2.73 ← **FOREX MARCH FLEXED EPS-ADS RANGE** → **$3.13**

Flex rate €1 : $1.30 £1 : $1.42 (based on **average March 09** rates)

$2.80 ← **FOREX JULY FLEXED EPS-ADS RANGE** → **$3.20**

Flex rate €1 : $1.37 £1 : $1.56 (based on **average of H1 and July 09** rates)

Specialty Pharma update

Michael Cola
President, Specialty Pharmaceuticals

Shire

Our purpose
We enable people with life-altering conditions to lead better lives

VYVANSE continues solid performance

- Holding market share during the Summer holidays when long-acting stimulants traditionally lose share
- Share trends in May and June reflect seasonality related to end of the school year and resulting drug holidays for pediatric patients
  - VYVANSE is disproportionately affected because it is predominantly a pediatric product (~70%) versus the market (~55%)*
  - The effect of the reduced volume in the pediatric segment is to shift the mix of business towards the adult segment during the Summer
  - Since VYVANSE has a lower share in the adult segment due to its more recent launch, the weighted average effect dampens overall share growth
  - VYVANSE share growth during Summer 2008 was unique due to launch of both the adult indication and the 13-hour data
- We have seen NO significant impact on VYVANSE from generic AXR
- We expect a strong “back to school” performance and continued steady progress in adult

*SDI May 2009 Vector One National, Pediatric defined as ages 6 - 17

The ADHD market is greatly impacted during Summer holiday



Source: IMS NPA Weekly

VYVANSE has held share despite the Summer holiday



Source: IMS NPA Monthly

* **12.3%** week ending July 24th 2009 IMS

VYVANSE pediatric share has continued to increase even during the Summer



Overall volume declines 30-35% in the pediatric segment from March to July

Sources: SDI Vector One National; IMS NPA Monthly

VYVANSE adult share continues to grow, but is lower than pediatric due to its more recent launch



As the adult segment is a seasonally higher portion of business, the weighted average effect dampens overall share growth

Sources: SDI Vector One National

The ADHD market continues to grow driven by the adult segment

June 2009 MAT Market Growth by Age Segment



Year to date market growth per IMS: 8.9%

Sources: Age Specific - SDI Vector One National; Overall - IMS

Generic AXR has taken share from the brand while total molecule share has remained flat, indicating no therapeutic substitution



Source: IMS NPA Monthly

Generic AXR has had little to no impact on VYVANSE

- In 2Q09 there were over 400,000 net switches to generic AXR*
  - 97% of those switches were from branded AXR or generic ADDERALL IR
  - < 1% of those switches were from VYVANSE (in fact, there were more switches from Concerta)
  - VYVANSE continues to draw more than 60% of its switch patients from products other than ADDERALL and ADDERALL XR

*IMS NPA Market Dynamics June 2009

Generic AXR has had little to no impact on VYVANSE

- VYVANSE has excellent 3rd Party reimbursement status and it continues to improve post introduction of generic ADDERALL XR with both Managed Care and Medicaid.

- Since April 1st, two large managed care organizations and two state Medicaid's have moved VYVANSE to preferred status on their formularies
  - In addition four smaller managed care organizations have also moved VYVANSE to preferred status
  - Generic XR remains significantly more expensive on average cost per prescription than VYVANSE

*IMS NPA Market Dynamics June 2009

We expect a strong 2H09 performance

- Back to school volume and pediatric market share bounce
- Strong market growth in adults
- Study 316 in adults (14-hour efficacy)
- Upside potential from GSK co-promotion

*IMS NPA Market Dynamics June 2009

INTUNIV received a Complete Response letter from the FDA

- Shire and FDA were not able to reach agreement on final product labeling in time to meet the PDUFA date (27-Jul-09)
- FDA did not identify safety concerns regarding INTUNIV or request new clinical data or additional analyses in the complete response letter
- Shire and FDA will continue to work together to resolve the remaining labeling language
- We anticipate a 4Q09 launch as planned

INTUNIV is a major opportunity for Shire in ADHD

- INTUNIV is a breakthrough non-scheduled product with demonstrated efficacy in ADHD patients with oppositional and disruptive symptoms
- INTUNIV will complement VYVANSE as it targets a different ADHD sub-population and should expand the market
- VYVANSE remains the cornerstone of our ADHD franchise

LIALDA: Continued strong performance

LIALDA TRx Volume and Share March 2007 – June 2009



GI franchise (LIALDA and PENTASA) has 33% NRx share of U.S. oral mesalamine market

Source: IMS Monthly NPA

New opportunities for core products will drive growth

- LIALDA global Phase 3 trials in diverticulitis are ongoing
- VYVANSE non-ADHD: Phase 2 clinical trials planned or underway with data anticipated 2H10
  - Adjunctive therapy in Depression
  - Cognitive Impairment in Depression
  - Negative Symptoms and Cognitive Impairment in Schizophrenia

We continue efforts to progress early pipeline products

- Early pipeline efforts are focused on investing in lower risk development of NCEs
  - Redesigning known molecules to create NCEs with improved attributes or enhanced PK/PD
- SPD 535 – Anagrelide analogue with platelet lowering ability and without PDEIII inhibition
  - Will initiate Phase 1 in 3Q09. Go/no-go based on established biomarkers
  - Initial PoC program targets prevention of thrombotic complications associated with arteriovenous grafts in hemodialysis
    - PoC for broader utility as an anti-coagulant
- CarrierWave
  - Activities underway primarily focused on NCE's in Pain and ADHD
  - More data available in 1Q10 on several products

HGT update

Sylvie Grégoire
President, Shire HGT

HGT product highlights

- ELAPRASE
  - Approved in 43 countries
  - Validation complete for new manufacturing facility
- REPLAGAL
  - Approved in Brazil in July
    - Now approved in 45 countries
  - EMEA approval of serum-free bioreactor manufacturing process
- FIRAZYR
  - Approved in 31 countries, launched in nine
  - US FAST-3 study initiated in June

HGT pipeline highlights

- velaglucerase alfa
  - Positive results in first of three Phase 3 trials
    - Significant increase in mean hemoglobin concentration
  - Fast Track designation
    - Initiated rolling NDA submission July 30
  - Treatment Protocol approved in US and open for enrollment
  - US filing Q3 2009 / EU filing Q4 2009

HGT product development pipeline

- HGT 1111(METAZYM) for MLD
  - Phase 2/3 study to start H2 2009
- Chaperone therapies
  - AMIGAL for Fabry - reviewing EMEA feedback
  - PLICERA for Gaucher - Phase 2 results H2 2009
- idursulfase-IT for Hunter CNS
  - Phase 1 to start H2 2009

Product development pipeline progression



* Currently on clinical hold

Concluding remarks

Angus Russell
CEO

Our purpose
We enable people with life-altering conditions to lead better lives

Concluding remarks

- Strong financial performance
  - Product sales excluding ADDERALL XR up 20%
  - Proactive cost management
  - 2009 guidance maintained
- Continuing momentum in our business
  - Drive growth in existing product portfolio
  - Launch new products
    - INTUNIV
    - velaglucerase alfa
  - Increase our global reach
  - Develop, advance and enhance our strong pipeline
- Aspiration to grow sales in the mid teens range on average between 2009 and 2015

Questions and Answers

APPENDIX

2009 Q2 Key financial ratios

FINANCIAL RATIOS (% of product sales)	Q2 09	Q4 08	y-o-y Growth	Q2 08	y-o-y Growth
Product sales			-21%		40%
Gross margin	84%	88%		88%	
R&D	21%	18%	-7%	18%	35%
SG&A	51%	40%	-5%	42%	18%
EBITDA[(1)] (% of product sales)	12%	38%		27%	
EBITDA[(2)] (% total revenue)	22%	35%		34%	

(1) Excluding royalties and other revenues.

(2) Including royalties and other revenues.

This slide contains non GAAP financial measures. See appendix for a list of items excluded from the GAAP equivalent to calculate these measures.

2009 Q2 Royalties

	Q2 2009 $m	Q2 2008 $m	Reported Growth	Like for Like Growth (1)
3TC	29	36	-18%	-11%
ZEFFIX	10	11	-6%	-2%
ADDERALL XR	14	-	n/a	n/a
Other	14	18	-25%	-19%
Total Royalties	67	65	+3%	+6%

(1) 'Like for Like Growth' excludes movements in average exchange rates, and is calculated after restating Q2 2009 results using Q2 2008 average foreign exchange rates.

2009 Q2 Operating income / EPS

	Q2 09 $m	Q2 08 $m	Reported Growth
Operating income / (loss)			
GAAP	35	(67)	+$102m
Adjustments	81	314	
Non GAAP[(1)]	116	247	-53%
EPS - ADS (diluted)			
GAAP	$0.24	($0.44)	+$0.68
Non GAAP[(1)]	$0.60	$0.95	-36%

(1) These are non GAAP financial measures. See appendix for a list of items excluded from the GAAP equivalent to calculate these measures.

2009 Q2 EPS Reconciliation

	Q2 09		Q2 08	
	$m	cents/ADS	$m	cents/ADS
US GAAP Net income / Diluted EPS (ADS)	**44.1**	**24.3c**	**(79.0)**	**(43.8c)**
Amortization and asset impairments	34.3	18.9c	121.4	63.0c
Acquisitions and integration activities	40.6	22.5c	135.0	70.2c
Divestments and re-organizations	5.9	3.3c	57.4	29.7c
Non GAAP adjustments to operating income	**80.8**	**44.7c**	**313.8**	**162.9c**
Discontinued operations	9.8	5.4c	-	-
Taxes on above adjustments	(25.6)	(14.1c)	(46.7)	(24.3c)
Non GAAP Net income / Diluted EPS (ADS)	**109.1**	**60.3c**	**188.1**	**94.8c**

2009 Q2 Cash generation reconciliation

	Q2 2009 $m	Q2 2008 $m
Net cash provided by operating activities	**72**	**180**
Tax and interest payments (net)	83	36
Payment for acquired and in-licensed products	37	136
Cash Generation	**192**	**352**

Presentation of 2008 R&D and SG&A

To be consistent with our 2009 presentation, for 2008 comparatives we have reclassified certain Medical Affairs costs related to promotional and marketing activities from R&D to SG&A, as follows:

All amounts in $ million

	2008 Q1		2008 Q2		2008 Q3		2008 Q4	
	As reported	Reclassified	As reported	Reclassified	As reported	Reclassified	As reported	Reclassified
US GAAP								
R&D	122.0	111.8	145.3	136.4	127.1	120.2	132.2	125.9
SG&A	334.5	344.7	428.8	437.7	320.4	327.3	339.2	345.5
	456.5	**456.5**	**574.1**	**574.1**	**447.5**	**447.5**	**471.4**	**471.4**
NON GAAP								
R&D	119.1	108.9	135.7	126.8	123.7	116.8	129.1	122.8
SG&A	287.4	297.6	289.6	298.5	276.7	283.6	282.6	288.9
	406.5	**406.5**	**425.3**	**425.3**	**400.4**	**400.4**	**411.7**	**411.7**

Non GAAP measures

- This presentation contains financial measures not prepared in accordance with US GAAP.
- These Non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of the Company's performance to historical results and to competitors' results. They should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.
- The following items are excluded from these non-GAAP financial measures:

Amortization and asset impairments:

- Intangible asset amortization and impairment charges; and
- Other than temporary impairment of investments.

Acquisitions and integration activities:

- Upfront payments and milestones in respect of in-licensed and acquired products;
- Costs associated with acquisitions, including transaction costs, and fair value adjustments on contingent consideration and acquired inventory;
- Costs associated with the integration of companies; and
- Incremental interest charges arising on the settlement of litigation with the former dissenting shareholders of TKT.

Divestments, re-organizations and discontinued operations:

- Gains and losses on the sale of non-core assets;
- Costs associated with restructuring and re-organization activities;
- Termination costs;
- Costs associated with the introduction of the new holding company; and
- Income / (losses) from discontinued operations.